TIMP-3 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-TIMP3
In stock
- SKU
- REC-TIMP3
Target Overview
TIMP-3 (Metalloproteinase inhibitor 3; UniProt P35625) is a secreted, ECM-bound member of the tissue inhibitor of metalloproteinases family, encoded by the TIMP3 gene. The full-length human precursor spans 211 amino acids and, unlike other TIMP family members, associates tightly with the extracellular matrix rather than circulating freely in body fluids. This recombinant form is produced in HEK293 mammalian cells, a system that supports the disulfide-bond architecture and glycosylation patterns characteristic of the native protein — features relevant when using the reagent for activity assays or binding studies where correct folding is required. TIMP-3 functions as a reversible, tight-binding inhibitor of zinc-dependent proteases. Its characterised targets include MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14, and MMP-15, as well as the ADAM-family sheddases ADAM10 and ADAM17. This breadth of inhibitory scope makes it a useful reagent for profiling protease selectivity in biochemical inhibition assays and for generating dose–response curves against individual MMPs or ADAMs under defined substrate conditions. Researchers use this recombinant in competitive inhibition assays to determine IC50 values against fluorogenic MMP substrates, in VEGFR-2/KDR binding displacement experiments, and as a positive control antigen for validating anti-TIMP-3 antibodies by Western blot or ELISA. Investigators requiring antibody validation standards can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-TIMP3), which has been validated for Western blot against human TIMP-3. The recombinant is also suitable as a reference standard for mass spectrometry-based proteomics workflows studying ECM composition and remodeling.
Background
Applications
- Fluorogenic MMP inhibition assay (IC50 determination against MMP-1, MMP-2, MMP-9, or MMP-13 using peptide-based substrates)
- ADAM10/ADAM17 (alpha-secretase) activity inhibition assay with fluorescent ectodomain substrate
- VEGFR-2/KDR binding displacement or competition ELISA to study VEGFA signalling blockade
- Recombinant antigen positive control for Western blot validation of anti-TIMP-3 antibodies (pairs with TPB antibody RP-TIMP3)
- ELISA capture/detection standard for quantification of TIMP-3 in conditioned medium or tissue lysates
- Protease selectivity profiling across the MMP/ADAM family in substrate competition formats
- ECM binding assay to characterise matrix-sequestration properties (heparan sulfate or fibronectin interaction)
- Mass spectrometry-based proteomics reference standard for absolute quantification of TIMP-3 in ECM-enriched fractions
References
- Giuffredi G et al. Mapping articular cartilage maturation across postnatal development by proteomics. Osteoarthritis Cartilage. 2026. doi:10.1016/j.joca.2026.06.006 [PMID: 42331135]
- Vandendriessche A et al. Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling. Cardiovasc Pathol. 2026. doi:10.1016/j.carpath.2026.107838 [PMID: 42303193]
- Bai H et al. The mechanisms of myricetin and quercetin in regulating miRNA-140 and MMP/TIMP signaling pathway in osteoarthritis treatment. Pak J Pharm Sci. 2026. doi:10.36721/PJPS.2026.39.8.226.1 [PMID: 42262200]
- Lin C et al. Platelet-rich plasma cues program M2 macrophage-derived exosome mimetics to regenerate the tendon-bone interface. J Nanobiotechnology. 2026. doi:10.1186/s12951-026-04626-5 [PMID: 42231327]
- Qian C et al. Effects of P38 MAPK Pathway Inhibition on the Metabolism of Periodontal Ligament Fibroblasts During Inflammation. J Cell Mol Med. 2026. doi:10.1111/jcmm.71223 [PMID: 42226340]
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Secreted; Extracellular matrix |
Frequently Asked Questions
What molecular weight should I expect for recombinant TIMP-3 on SDS-PAGE or Western blot?
The full-length human TIMP-3 precursor is 211 amino acids with a predicted unglycosylated MW of ~24 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation shifts the apparent MW on reducing SDS-PAGE to approximately 27–30 kDa, consistent with the native secreted form. Under non-reducing conditions, intramolecular disulfide bonds can further alter migration. If you are running a Western blot positive control alongside our matched antibody RP-TIMP3, expect the primary band in the 27–30 kDa range; a faint higher-MW band from glycoform heterogeneity is occasionally observed.
Is this recombinant TIMP-3 the full-length precursor or a processed mature form?
This product corresponds to the full-length human TIMP-3 precursor (UniProt P35625, residues 1–211), including the native signal peptide region. The secreted mature form — generated after signal peptide cleavage — begins at approximately residue 24, so the predominant species in solution represents the processed, secretion-competent protein. No pro-domain truncation is introduced. The HEK293 expression system supports the complete 12-cysteine disulfide framework critical for TIMP-3 folding and its characteristic tight ECM association, which is relevant if you are using this reagent in matrix-binding or surface plasmon resonance assays.
Which MMPs and ADAMs does recombinant TIMP-3 inhibit, and how broad is its selectivity?
TIMP-3 has one of the broadest inhibitory profiles in the TIMP family. Characterised MMP targets include MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 (MT1-MMP), and MMP-15 (MT2-MMP). Beyond classical MMPs, TIMP-3 is the only TIMP family member known to potently inhibit ADAM-family sheddases, including ADAM10 and ADAM17 (TACE). This dual MMP/ADAM inhibitory scope makes it useful for dissecting shedding events from matrix remodeling in the same experiment. If you need to profile selectivity across a panel of zinc-dependent proteases, TIMP-3 covers both sub-families in a single reagent.
What fluorogenic substrate and assay buffer should I use to measure TIMP-3 inhibitory activity?
For MMP inhibition assays, Mca-KPLGL-Dpa-AR-NH2 (a quenched fluorogenic peptide, ex/em ~320/405 nm) is a well-validated substrate for MMP-2, MMP-9, and MMP-13 titration experiments. Run reactions in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35 at 37°C — the Brij-35 prevents surface adsorption of both the enzyme and inhibitor. Note that TIMP-3's tight ECM-binding character can cause non-specific adsorption to polystyrene microplate surfaces; use BSA-blocked low-binding plates and keep incubation times consistent across replicates to minimise this variable.
What starting concentration and pre-incubation time should I use for a TIMP-3 IC50 assay against MMP-9?
For a standard IC50 titration against MMP-9, start with a TIMP-3 concentration range of 0.1–100 nM (serial 3-fold dilutions, 8–10 points). Pre-incubate TIMP-3 with MMP-9 for 30–60 minutes at 37°C before adding substrate — TIMP-3 is a tight-binding, slow-on inhibitor, and shorter pre-incubation underestimates potency. Reported Ki values for TIMP-3/MMP-9 are in the low-nanomolar to sub-nanomolar range; if your calculated IC50 is significantly higher than 5–10 nM, verify that MMP-9 is fully activated (pro-domain removed) and that the assay buffer contains at least 5 mM CaCl2 for metalloproteinase stability.
What is the storage buffer for recombinant TIMP-3 and can I dilute it directly into cell culture media?
This product is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol. For cell-based assays, dilute at least 1:10 into serum-free or low-serum media immediately before use to reduce glycerol to ≤1% (higher concentrations can affect cell viability). Pre-dilute in PBS or assay buffer as an intermediate step if the working concentration requires a smaller final dilution. Protein should be aliquoted upon first receipt, stored at -20°C, and used within 12 months; repeated freeze-thaw cycles measurably reduce inhibitory activity given TIMP-3's disulfide-dependent fold.
Can I use recombinant TIMP-3 as a positive control for Western blot with the RP-TIMP3 antibody?
Yes — this recombinant (REC-TIMP3) was specifically produced to pair with the RP-TIMP3 rabbit polyclonal antibody as a confirmed positive control. Load 20–50 ng of REC-TIMP3 per lane on a standard 12% SDS-PAGE gel under reducing conditions; the antibody detects the glycosylated band at 27–30 kDa with high signal-to-noise at dilutions of 1:1,000–1:2,000. This pairing is also useful for antibody titration experiments — running a dilution series of REC-TIMP3 alongside your cell lysate allows you to bracket the endogenous band and confirm linearity before committing to a full experimental Western blot.
How much recombinant TIMP-3 should I load as a positive control alongside RP-TIMP3 antibody in a Western blot?
For most Western blot setups using RP-TIMP3, 20–50 ng of REC-TIMP3 per lane is sufficient to produce a clean, unambiguous band at 27–30 kDa without overloading. If you are running high-sensitivity chemiluminescent detection (e.g., ECL Plus or a digital imager), start at 20 ng; for colorimetric or less sensitive substrates, 50 ng is a safer starting point. Include this lane adjacent to your cell or tissue lysates so the band position unambiguously identifies endogenous TIMP-3 signal, which can run slightly differently depending on the glycosylation state of the biological sample.
Validation imagery coming soon
Western blot validation figures for REC-TIMP3 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.